What a fish can learn from a mouse: Principles and strategies for modeling human cancer in mice

Zebrafish

Volumn 6, Issue 4, 2009, Pages 329-337

  Bailey, Jennifer M ^a   Creamer, Bradley A ^a   Hollingsworth, Michael A ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ARTICLE; DISEASE MODEL; GENE TRANSFER; GENETICS; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; TRANSPOSON; ZEBRA FISH;

ANIMALS; DISEASE MODELS, ANIMAL; DNA TRANSPOSABLE ELEMENTS; GENE TRANSFER TECHNIQUES; MICE; NEOPLASMS; RNA INTERFERENCE; ZEBRAFISH;

DANIO RERIO; MUS; MUS MUSCULUS;

EID: 74049105523     PISSN: 15458547     EISSN: None     Source Type: Journal    
DOI: 10.1089/zeb.2009.0626     Document Type: Article

References (105)

1. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-2715.
2. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007;2:1998-2004.
3. Acevedo-Arozena A, et al. ENU mutagenesis, a way forward to understand gene function. Annu Rev Genomics Hum Genet 2008;9:49-69.
4. Palmiter RD, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982;300:611-615.
5. van den Pol AN, Ghosh PK. Selective neuronal expression of green fluorescent protein with cytomegalovirus promoter reveals entire neuronal arbor in transgenic mice. J Neurosci 1998;18:10640-10651.
6. Fritschy JM, et al. Brain cell type specificity and gliosisinduced activation of the human cytomegalovirus immediate-early promoter in transgenic mice. J Neurosci 1996;16:2275-2282.
7. Schmidt EV, Christoph G, Zeller R, Leder P. The cytomegalovirus enhancer: a pan-active control element in transgenic mice. Mol Cell Biol 1990;10:4406-4411.
8. Prosch S, et al. Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 1996;377:195-201.
9. Brooks AR, et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004;6: 395-404.
10. Meier JL. Reactivation of the human cytomegalovirus major immediate-early regulatory region and viral replication in embryonal NTera2 cells: role of trichostatin A, retinoic acid, and deletion of the 21-base-pair repeats and modulator. J Virol 2001;75:1581-1593.
11. Mehta AK, Majumdar SS, Alam P, Gulati N, Brahmachari V. Epigenetic regulation of cytomegalovirus major immediate-early promoter activity in transgenic mice. Gene 2009;428:20-24.
12. Qu P, Du H, Li Y, Yan C. Myeloid-specific expression of Api6=AIM=Sp alpha induces systemic inflammation and adenocarcinoma in the lung. J Immunol 2009;182:1648-1659.
13. Liu RS, et al. Specific activation of sodium iodide symporter gene in hepatoma using alpha-fetoprotein promoter combined with hepatitis B virus enhancer (EIIAPA). Anticancer Res 2009;29:211-221.
14. Zambrowicz BP, et al. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. Proc Natl Acad Sci U S A 1997;94:3789-3794.
15. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999;21:70-71.
16. Awatramani R, Soriano P, Mai JJ, Dymecki S. An Flp indicator mouse expressing alkaline phosphatase from the ROSA26 locus. Nat Genet 2001;29:257-259.
17. Strathdee D, Ibbotson H, Grant SG. Expression of transgenes targeted to the Gt(ROSA)26Sor locus is orientation dependent. PLoS One 2006;1:e4.
18. Krane IM, Leder P. NDF=heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996;12:1781-1788.
19. Sandgren EP, et al. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 1995;55:3915-3927.
20. Fukazawa T, et al. Pulmonary adenocarcinoma-targeted gene therapy by a cancer-and tissue-specific promoter system. Mol Cancer Ther 2007;6:244-252.
21. Hingorani SR, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7:469-483.
22. Connolly DC, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389-1397.
23. Herve J, et al. Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumorspecific promoter. Hum Gene Ther 2008;19:915-926.
24. Yoshida T, Murata K, Shiraki N, Kume K, Kume S. Analysis of gene expressions of embryonic stem-derived Pdx1-expressing cells: implications of genes involved in pancreas differentiation. Dev Growth Differ 2009;51:463-472.
25. Metzger D, Chambon P. Site-and time-specific gene targeting in the mouse. Methods 2001;24:71-80.
26. Zheng B, Mills AA, Bradley A. A system for rapid generation of coat color-tagged knockouts and defined chromosomal rearrangements in mice. Nucleic Acids Res 1999;27: 2354-2360.
27. Schmidt-Supprian M, Rajewsky K. Vagaries of conditional gene targeting. Nat Immunol 2007;8:665-668.
28. Toxic alert. Nature 2007;449:378.
29. Feldmann G, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57:1420-1430.
30. Vincent DF, et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 2009;5:e1000575.
31. Morris ZS, McClatchey AI. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma. Proc Natl Acad Sci U S A 2009;106:9767-9772.
32. Lin PP, et al. EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. Cancer Res 2008;68:8968-8975.
33. McCarty JH, et al. Genetic ablation of alphav integrins in epithelial cells of the eyelid skin and conjunctiva leads to squamous cell carcinoma. Am J Pathol 2008;172:1740-1747.
34. Ma WL, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008;135:947-955, 955.e1-5
35. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000;26:99-109.
36. Nakano M, et al. Efficient gene activation in cultured mammalian cells mediated by FLP recombinase-expressing recombinant adenovirus. Nucleic Acids Res 2001;29:E40.
37. Bischof J, Basler K. Recombinases and their use in gene activation, gene inactivation, and transgenesis. Methods Mol Biol 2008;420:175-195.
38. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007;7:645-658.
39. Haller O, FreseM, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses. Rev Sci Tech 1998;17:220-230.
40. Schneider A, Zhang Y, Guan Y, Davis LS, Breyer MD. Differential, inducible gene targeting in renal epithelia, vascular endothelium, and viscera of Mx1Cre mice. Am J Physiol Renal Physiol 2003;284:F411-F417.
41. Torchia EC, Boyd K, Rehg JE, Qu C, Baker SJ. EWS=FLI-1 induces rapid onset of myeloid=erythroid leukemia in mice. Mol Cell Biol 2007;27:7918-7934.
42. Loonstra A, et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A 2001;98:9209-9214.
43. Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation=inactivation in the mouse. Dev Biol 2002;244:305-318.
44. Zhang Y, et al. Inducible site-directed recombination inmouse embryonic stem cells. Nucleic Acids Res 1996;24:543-548.
45. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007;11:375-388.
46. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992;89:5547-5551.
47. Ewald D, et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science 1996; 273:1384-1386.
48. Creamer BA, Triplett AA, Wagner KU. Longitudinal analysis of mammogenesis using a novel tetracycline-inducible mouse model and in vivo imaging. Genesis 2009;47:234-245.
49. Zeng H, et al. An inducible and reversible mouse genetic rescue system. PLoS Genet 2008;4:e1000069.
50. Silva JM, et al. Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 2005;37:1281-1288.
51. Dickins RA, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005;37:1289-1295.
52. Wiznerowicz M, Szulc J, Trono D. Tuning silence: conditional systems for RNA interference. Nat Methods 2006;3: 682-688.
53. Hemann MT, et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003;33:396-400.
54. Dickins RA, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet 2007;39:914-921.
55. Zender L, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008;135:852-864.
56. Hashimoto M, et al. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci 2009;100:730-736.
57. Cheung AF, Dupage MJ, Dong HK, Chen J, Jacks T. Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer. Cancer Res 2008;68:9459-9468.
58. Goren I, et al. A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am J Pathol 2009;175:132-147.
59. Uronis JM, et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009;4:e6026.
60. Sayi A, et al. The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009;182:7085-7101.
61. Van der Sluis M, et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-129.
62. Ivics Z, Izsvak Z, Minter A, Hackett PB. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci U S A 1996;93:5008-5013.
63. Radice AD, Bugaj B, Fitch DH, Emmons SW. Widespread occurrence of the Tc1 transposon family: Tc1-like transposons from teleost fish. Mol Gen Genet 1994;244:606-612.
64. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-510.
65. Collier LS, Largaespada DA. Transposons for cancer gene discovery: Sleeping Beauty and beyond. Genome Biol 2007;8 Suppl 1:S15.1-S15.8.
66. Dupuy AJ, Jenkins NA, Copeland NG. Sleeping Beauty: a novel cancer gene discovery tool. Hum Mol Genet 2006;15 Spec No. 1:R75-R79.
67. Ding S, et al. Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 2005;122: 473-483.
68. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005;436:272-276.
69. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005; 436:221-226. (Pubitemid 41021267)
70. McElroy M, Bouvet M, Hoffman RM. Chapter 2. Colorcoded fluorescent mouse models of cancer cell interactions with blood vessels and lymphatics. Methods Enzymol 2008; 445:27-52.
71. Yang M, et al. Whole-body and intravital optical imaging of angiogenesis in orthotopically implanted tumors. Proc Natl Acad Sci U S A 2001;98:2616-2621.
72. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-359.
73. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y. "Green mice" as a source of ubiquitous green cells. FEBS Lett 1997;407:313-319.
74. Hoffman R. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 2002;3:546-556.
75. Yang M, et al. Transgenic nude mouse with ubiquitous green fluorescent protein expression as a host for human tumors. Cancer Res 2004;64:8651-8656.
76. McKinney SA, Murphy CS, Hazelwood KL, Davidson MW, Looger LL. A bright and photostable photoconvertible fluorescent protein. Nat Methods 2009;6:131-133.
77. Wacker SA, Oswald F, Wiedenmann J, Knochel W. A green to red photoconvertible protein as an analyzing tool for early vertebrate development. Dev Dyn 2007;236: 473-480.
78. Tomura M, et al. Monitoring cellular movement in vivo with photoconvertible fluorescence protein "Kaede" transgenic mice. Proc Natl Acad Sci U S A 2008;105:10871-10876.
79. Kim JB, Stein R, O'Hare MJ. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis. Tumour Biol 2005;26:173-185.
80. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285: 116-126.
81. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. J Oncol 2009;2009:950201.
82. Kota J, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137: 1005-1017.
83. Chan IT, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004;113:528-538.
84. Badea TC, Wang Y, Nathans J. A noninvasive genetic= pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci 2003;23: 2314-2322.
85. Haldar M, Hedberg ML, Hockin MF, Capecchi MR. A CreER-based random induction strategy for modeling translocation-associated sarcomas in mice. Cancer Res 2009; 69:3657-3664.
86. Ratnacaram CK, et al. Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma. Proc Natl Acad Sci U S A 2008;105:2521-2526.
87. Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci U S A 2005;102:10898-10903.
88. Postic C, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cellspecific gene knock-outs using Cre recombinase. J Biol Chem 1999;274:305-315.
89. Sekine S, et al. Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis. Gastroenterology 2009;136:2304-2315.e1-4
90. Gannon M, Shiota C, Postic C, Wright CV, Magnuson M. Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis 2000;26:139-142.
91. Rucker EB 3rd, et al. Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. Mol Endocrinol 2000;14:1038-1052.
92. Hager JH, Ulanet DB, Hennighausen L, Hanahan D. Genetic ablation of Bcl-x attenuates invasiveness without affecting apoptosis or tumor growth in a mouse model of pancreatic neuroendocrine cancer. PLoS One 2009;4:e4455.
93. Hingorani SR, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003;4:437-450.
94. Kawaguchi Y, et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 2002;32:128-134.
95. Tinder TL, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181:3116-3125.
96. Vooijs M, van der Valk M, te Riele H, Berns A. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene 1998;17:1-12.
97. Harada N, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J 1999;18:5931-5942.
98. Arango NA, et al. Conditional deletion of beta-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Dev Biol 2005;288:276-283.
99. Tanwar PS, et al. Constitutive activation of beta-catenin in uterine stroma and smooth muscle leads to the development of mesenchymal tumors in mice. Biol Reprod 2009;18:545-552.
100. Boerboom D, et al. Misregulated Wnt=beta-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res 2005;65:9206-9215.
101. Tian H, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci U S A 2009;106:4254-4259.
102. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res 2007;67: 4869-4877.
103. Said N, et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009; 28:3487-3498.
104. Dou GR, et al. RBP-J, the transcription factor downstream of Notch receptors, is essential for the maintenance of vascular homeostasis in adult mice. FASEB J 2008;22:1606-1617.
105. Kuhnert F, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development 2008;135:3989-3993.